Senior Leadership Team

Mr. Grossman has been the driving force behind ADMA Biologics’ mission to develop and commercialize novel plasma-derived products to address certain unmet medical needs for immune compromised patients.

His career began as a hospital-based plasma products sales representative focusing on immune compromised patients. This early experience gave him valuable insight into the challenges faced by these patients, while also deepening his understanding of how clinicians approach their care. With over 25 years of experience in the blood and plasma products industry, Mr. Grossman has a proven track record of launching new products, building and managing national and international sales forces as well as managing and designing clinical trials. Additionally, he has negotiated and completed numerous business development transactions. Under his leadership, Mr. Grossman brought ADMA public in 2013 and has completed over $1.2 billion in equity capital markets financing and debt transactions throughout his career.

Mr. Grossman led the asset acquisition of the Biotest Therapy Business Unit in 2017, which transformed ADMA Biologics into one of a handful of vertically integrated plasma products manufacturing companies based in the US. Subsequent to the asset acquisition, he is credited with leading the successful integration of business operations, revamping and overhauling the site-wide quality and compliance functions and leading the regulatory affairs strategy resulting in FDA approvals for BIVIGAM®’s Prior Approval Supplement (PAS) and ASCENIV™’s Biologics License Application (BLA), as well as the receipt of a new FDA license for the Boca Raton manufacturing plant.

Mr. Grossman has been a member of the ADMA Biologics Board of Directors since 2007, serving as the Company’s President and Chief Executive Officer since October 2011, and as the Company’s President and Chief Operating Officer between 2007 and October 2011. In 2016, he was issued several patents, which are the basis for the unique manufacturing methods and composition for ASCENIV™. Prior to founding ADMA, Mr. Grossman was the Executive Vice President of National Hospital Specialties and GenesisBPS, positions he held between 1994 and 2011. Previously, he worked at MedImmune, Inc. as part of the marketing team for respiratory syncytial virus and cytomegalovirus immunoglobulins and at the American Red Cross, where he participated in the launch of new products with the Biomedical Services division. Mr. Grossman currently serves as the Chair of the North America Board of Directors of the Plasma Protein Therapeutics Association, since September 2023.

Mr. Grossman is a graduate of American University, receiving a BS in Business Administration, with a specialization in International Business and Marketing.

As Chief Operating Officer & Senior Vice President of Compliance for ADMA Biologics, Ms. Kestenberg is responsible for ensuring Company activities comply with regulations and the expectations of governing bodies as well as oversees company-wide project planning, project management, and oversight for clinical programs and operations.

Along with the executive team, Kaitlin was instrumental in conducting due diligence on the Biotest Therapy Business Unit acquisition as well as playing an integral role in integration of corporate operations, compliance and FDA-regulated functions. She led significant portions of ADMA’s compliance and quality assurance overhaul, worked on teams developing novel regulatory affairs strategies, led the team responsible for drafting the ASCENIV™ BLA and other significant regulatory submissions and is credited with preparing the company for a successful FDA inspection post acquisition. Ms. Kestenberg has participated in and led numerous FDA interactions for ADMA and has attended multiple face-to-face FDA meetings during her tenure.

Ms. Kestenberg joined ADMA Biologics as Clinical Research Manager in 2011 and has received multiple promotions and positions of increasing responsibility. Prior to joining ADMA, she held roles of increasing responsibility in clinical operations, quality operations and compliance at Acorda Therapeutics and Merck.

Ms. Kestenberg has over 12 years of project management and clinical operations experience including successful Phase 3 clinical trials and subsequent regulatory filings. She was responsible for all operational aspects and site management and oversite of ADMA’s Phase 3 clinical program used as the basis for ADMA’s drug approval for ASCENIV™. She has led cross-functional teams across numerous therapeutic areas including immunology, infectious diseases, multiple sclerosis, congestive heart failure, acute spinal cord injury, HIV, hepatitis Clostridioides difficile, and diabetes.

She holds a BA from the State University of New York at Albany and an MSJ from Seton Hall University.

Mr. Tade is the Chief Financial Officer & Treasurer of ADMA Biologics. He joined the company in June 2023 as Vice President of Financial Operations. Before joining ADMA, Mr. Tade served as Vice President of Finance for Commercial Packaging Technology and Development and Manufacturing at PCI Pharma Services. Prior to that, he held the role of Vice President of Finance for Operations & Quality at Baxter in Illinois and Vice President of Operations Finance at Becton Dickinson in Switzerland. With over 20 years of experience in the medical device industry, Mr. Tade has led global supply chain and manufacturing operations finance teams across multiple countries and multinational organizations.

He holds a Bachelor of Science degree in Finance from California State University, Long Beach, and a Master of Arts degree in Organizational Leadership from Gonzaga University.

Mr. Chambers joined ADMA Biologics in April 2023 as the Vice President, Quality. He is responsible for ensuring the continued high-performance of ADMA’s Quality Management System, while partnering closely with development, manufacturing, and commercial colleagues to drive a culture of quality excellence and compliance.

Prior to joining ADMA, Mr. Chambers was the Vice President of Global Quality at VBI Vaccines where he led the quality organization during the development and commercial launch of the company’s lead hepatitis B vaccine candidate. Mr. Chambers has more than 25 years of experience in the field of quality and has successfully led multiple regulatory inspections, both foreign and domestic. His broad background includes quality and operational leadership positions at Merck, Charles River Laboratories, BioReliance, and ElevateBio.

Mr. Chambers holds a BS in Biology from Western Carolina University.

Mr. Daniel Garcia is Vice President of IgG Product Management for ADMA Biologics and is responsible for management of IgG products, serving on strategic business and continuous improvement assignments.  

Mr. Garcia joined ADMA Biologics in April of 2016 as the VP of Manufacturing and Technical Operations. Prior to joining ADMA he was Senior Production Manager at Baxter Healthcare, an integral team member developing a new IGIV product. As Senior Director of Operations and Technical Development at Emergent Biosolutions, Mr. Garcia was on the development team and later headed the manufacturing and process development functions in the production of an anthrax vaccine (Biothrax), a commercial vaccine for the DOD in support of US Military personnel. At Shanghai RAAS Blood Products, Mr. Garcia led a project as VP of Operations, constructing a 3 million liter automated blood fractionation plant in compliance with US FDA, EMEA and ISO-9001 accreditation standards. Mr. Garcia served as COO at Biocell Laboratories where he was responsible for developing and commercializing numerous FDA-approved clinical controls, calibrators and medical devices.  At Molecular GPS, as VP of Manufacturing, Mr. Garcia designed and constructed a cGMP modular cleanroom production facility to manufacture targeted small molecule anti-cancer therapeutics and vaccines.

With over 30 years of Pharmaceutical, Manufacturing, and Operations experience in production of FDA-licensed small volume parenteral therapeutics, vaccines and medical devices, Mr. Garcia led development, manufacturing and engineering teams across numerous therapeutic areas. He holds a BA from California State University Los Angeles and an MS from California State University Northridge.

Mr. Janek joined ADMA Biologics in May of 2021. Prior to joining ADMA, Mr. Janek was a Site Head and integral team member of the Plasma Leadership Team with Takeda. Mr. Janek started his career in 1994 with Alcon Laboratories, an ophthalmic pharmaceutical company in Fort Worth, Texas, and he went on to serve Alcon for 20 years in roles of increasing management responsibility, including the last 6 years with Alcon as a Site Head in Sao Paulo, Brazil.  Mr. Janek returned to North America in 2014 and held positions of increasing responsibility from Associate Director with Gilead to Site Head with Takeda.

With over 30 years of operations management experience in aseptic formulation, aseptic filling and finishing, including more than 10 years in a Site Head capacity leading manufacturing of globally regulated and licensed pharmaceuticals, biologics (plasma), and medical devices, Mr. Janek has built a strong career in highly technical environments across multiple countries, companies and sites.

Mr. Janek has a proven track record in putting the patient first by improving manufacturing operations, driving regulatory compliance, improving safety, deploying Lean Six Sigma, assuring business continuity, leading turn-around, developing people and teams, and building and growing cost-competitive organizations.

Mr. Janek is an iTLS Certified Expert and Black Belt in Theory of Constraints, Lean Six Sigma. He holds a BA in Biology from Texas A&M University and an MS in Pharmaceutical Manufacturing from Stevens Institute of Technology.

As Vice President, Market Access and National Accounts for ADMA Biologics, Mr. Least brings experience of more than 30 years in the healthcare industry with a focus on specialty product manufacturing, sales, distribution, and commercial operations. Previously as Vice President of Sales for ASD Healthcare, he helped to grow specialty distribution from $9B to over $15B in annual sales. Mr. Least has held various roles and responsibilities including sales, sales leadership, marketing, medical affairs, training, account management, business development, and executive leadership. He has worked for large premier manufacturers and distributors (Searle, Pfizer, Eisai, Johnson & Johnson, AmerisourceBergen), as well as entrepreneurial biotech companies. His extensive knowledge and expertise has resulted in consistent success, with a unique perspective of the US specialty care market and the challenges facing manufacturers, distributors, healthcare providers, health systems, and academic medical centers of excellence.

Mr. Pantello is Vice President of Marketing and Corporate Development for ADMA Biologics. He is responsible for leading marketing and business development efforts across all the ADMA immunoglobulin brands.

Prior to joining ADMA Biologics in January of 2018, Mr. Pantello was the account management lead supporting ADMA’s launch preparation activities at H4B Chelsea and Havas Health. At H4B/Havas, he worked hand in hand with the executive team at ADMA Biologics for more than 4 years dissecting the layers of the plasma products market, leading all market research and focus group activities to gain insights and form the basis for the company’s marketing strategies. Drew brings to ADMA the experience of holding various roles of increasing responsibility and working on product launches across a wide range of therapeutic categories for more than 20 years in pharmaceutical market research, advertising, and marketing. He has held positions at LM&P, Euro RSCG Life, H4B Chelsea, and Havas Health across Account Management and Business Development functions. He was responsible for leading numerous major product launches for brands across immunology, HIV, infectious disease, diabetes, and neuroscience.

Mr. Pantello holds a BA in History from Ramapo College of New Jersey.

Mr. Space is the Vice President, Long Range Planning & Analysis.

He joined ADMA Biologics in September 2018. Prior to this, he worked for Hoffman-La Roche, holding leadership positions in process development, engineering, production, supply chain, finance, IT, and site management. With Roche, he worked at several sites across the United States and internationally.

Mr. Space has more than 30 years of varied operational experience in the pharmaceutical industry. He led significant capital projects including the design and construction of a $50 million vitamin plant and a $350 million Greenfield active pharmaceutical ingredient facility. He led a supply chain expansion program for an antiviral targeted at the prevention and treatment of a threatened global influenza pandemic.

Mr. Space holds an MA in Business Administration from Rutgers University and a BA in Chemical Engineering from the University of Delaware.

As the Vice President, Operations for ADMA BioCenters, Mr. Stremming is responsible for overseeing all aspects of the Plasma Services organization, including driving plasma collections and revenue growth, quality control, and ensuring continued regulatory compliance across all ADMA BioCenters. Mr. Stremming works closely with cross-functional teams within both ADMA BioCenters and ADMA Biologics to identify opportunities for process optimization and cost reduction, while building and maintaining relationships with key industry partners and stakeholders.

Mr. Stremming joined ADMA BioCenters in April 2023. Prior to joining ADMA, Mr. Stremming was the President of Interstate Blood Bank, Inc., President of BPC, and Vice President of the Southeast Plasma Business Unit within the Grifols Organization. Mr. Stremming started his career as a Center Manager in 2000 with Alpha Therapeutic, a plasma company headquartered in Los Angeles, CA. Over the past 20 years, Mr. Stremming worked at Grifols with increasing responsibilities. His roles included Regional Operations Manager, Associate Director of Operations, Director of Program Management, Senior Director of Business Integration (M&A), and finally Vice President of Southeast Plasma Operations.

He holds a BA from Washburn University, as well as certifications in Lean Six Sigma, Project Management, and Mergers & Acquisitions.

Dr. Gruenglas is Executive Director, Government Affairs, Health Policy and Scientific Communications, at ADMA Biologics. In this capacity, he works with federal and state stakeholders to develop and advocate for policy that impacts the IVIG therapeutic area, plasma-derived therapies, and biopharmaceuticals. In this role he conducts research in policy, pharmacoeconomics, and ethics. Prior to this he was a Managing Partner and Executive Vice President for several life science consultancies, with a focus on oncology commercialization, health policy, and managed care. Dr. Gruenglas earned his doctorate in health sciences from Massachusetts College of Pharmacy and Health Sciences, where he was elected to Phi Kappa Phi and Alpha Eta honor societies. He holds MAs in bioethics from Harvard Medical School and English Literature from Brooklyn College-CUNY, and a Certificate in Legislative Studies from the Government Affairs Institute at Georgetown University. Dr. Gruenglas is faculty at the College of Arts & Sciences, Boston University, and serves as a volunteer firefighter/EMT in Massachusetts.

John Hafl brings a wealth of expertise to his role as Executive Director of Sales at ADMA Biologics, with 25 years of experience in the healthcare industry. Specializing in immune globulins and other biologic products, John has played a pivotal role in the growth of prestigious companies such as Johnson & Johnson, Bayer Biological, Talecris Biotherapeutics, Kedrion Biopharma, Coram, Kroger Specialty Infusion, HPC Specialty Pharmacy, BDI Pharmaceuticals, and CSI Specialty Group.

John's career began as a specialty sales representative, where his exceptional performance quickly propelled him into leadership positions. He has excelled in various functions, including hospital sales, sales training, national accounts, advocacy, and business development. His comprehensive understanding of the industry and proven leadership skills have consistently driven sales teams to achieve outstanding results.

In addition to his corporate accomplishments, John is a respected speaker at industry conferences. He shares his knowledge on building and leading high-performing teams, as well as his insights into current industry trends and critical topics for sales organizations.

John holds a BA degree from the University of Cincinnati.

Ms. Klostermeyer is the Executive Director, Supply Chain for ADMA Biologics. She is responsible for logistics, inventory control, distribution of finished goods, and production scheduling. She develops strategic plans and processes to improve productivity, quality, and efficiency of operations.

Ms. Klostermeyer has over 20 years’ experience in the biologics industry. She has held management positions with increasing responsibility at the ADMA Biologics manufacturing site across Supply Chain, Accounting and Information Technology.

Ms. Klostermeyer holds a BA in operations management from Florida Atlantic University in Boca Raton, FL.